A 4-week vancomycin pulse and taper regimen may be a safe and effective strategy to delay or prevent Clostridioides difficile ...

Paul Feuerstadt, MD, FACG, AGAF, discusses how testing for Clostridioides difficile is recommended for hospitalized patients or outpatients with new-onset, unexplained diarrhea who have risk factors ...

A common practice for treating patients with gastrointestinal conditions has been revised by the American Gastroenterological Association, it announced Feb. 21. The group has expanded its ...

Researchers may not yet understand the mechanism behind recurrent Clostridium difficile infections, but they may have isolated five risk factors, according to a study published in Infection Control & ...

The panelist discusses how recurrent Clostridioides difficile infections involve complex differential diagnosis, including persistent infection, reinfection, and other gastrointestinal conditions.

Vowst is a prescription drug that’s used in adults to help prevent Clostridioides difficile (C. diff) infection from coming back after it has been treated. Vowst comes as an oral capsule. Vowst ...

A novel vaccination approach developed by Vanderbilt Health researchers cleared the harmful gut bacterium Clostridioides difficile (C. diff) in an animal model of infection. An experimental vaccine ...

The bacterium Clostridioides difficile is named “difficult” for a reason. Originally, it was hard to grow in the lab, and, now, it’s the source of gut infections that are tough to treat. About half a ...

— Greg Vigna, M.D., J.D. SANTA BARBARA, CA, UNITED STATES, August 3, 2023/EINPresswire.com/ -- “Prolonged IV antibiotics are necessary for the treatment of Grade ...

Dear Dr. Roach: About one year ago, I had Clostridioides difficile (C. diff) that was treated with 125 mg of vancomycin for about four weeks. I had none of the usual risk factors, and the cause was ...

Three recent studies tackled strategies aimed at preventing recurrent Clostridium difficile infection (RCDI). Adding a single dose of bezlotoxumab—a monoclonal antibody that neutralized C difficile ...